News

Gennisium grants exclusive licence agreement to Mercapharm for Gencebok® in Poland

Gennisium grants exclusive licence agreement to AxxessBio (Singapore) for Gencebok® in South-East Asian countries

Gennisium grants exclusive licence agreement to Nordic Prime (Denmark) for Gencebok® in the Nordics

Gennisium grants exclusive licence agreement to Global Farma (Guatemala) for Gencebok® in Central America, Caribbean and Venezuela

European Commission grants Marketing Autorisation to Gencebok®, further to positive opinion delivered by EMA

CHMP grants positive opinion to Gencebok®, 10 mg/ml solution for infusion (1 ml ampoule), for i.v. and oral use

Gennisium grants exclusive licence agreement to Reach-Pharma (Australia) for Gencebok® in Australia, New-Zealand and Papua-New Guinea

Gennisium expands its presence in the most important markets in Latin America, Mexico and Brazil, in granting exclusive promotion rights to Moksha8 for Gencebok®

Gennisium is incubated by the French public company Paris Biotech Santé, which supports start-ups specialised in Health area and is located at Paris

First European marketing authorization application submitted by Gennisium to EMA for caffeine citrate (Gencebok® ; centralised procedure – hybrid application). Caffeine citrate is indicated in premature newborns for the treatment of primary apnoea